Finding new treatments for acute myeloid leukemia by targeting a specific protein.
Official title: Screening for Inhibitors of the Chromatin Reader SGF29
Funded at Sanford Burnham Prebys Medical Discovery Institute · NIH-11168638 · Data updated 2026-11-12
This study is looking at ways to treat acute myeloid leukemia (AML) by targeting a protein called SGF29, which helps cancer cells grow, to see if blocking it can stop the disease from getting worse.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sanford Burnham Prebys Medical Discovery Institute NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | April 8, 2025 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $768,437 |
| NIH project number | 1R01CA301721-01 |
| Project ID | NIH-11168638 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia, particularly those with specific genetic mutations.
✕Less likely to help
Patients with other types of leukemia or those whose AML does not involve the targeted pathways may not benefit from this research.
What this research studies
This research focuses on acute myeloid leukemia (AML), a severe blood cancer with low survival rates. The team aims to identify therapies that can target common molecular pathways affected by various mutations in AML. By inhibiting a protein called SGF29, which plays a role in the activation of cancer-related genes, the researchers hope to block the growth of leukemia cells. The study employs various advanced techniques to explore how targeting SGF29 can lead to effective treatments for different subtypes of AML.
Why it matters
Potential benefit: If successful, this research could lead to new, more effective treatments for a significant number of AML patients.
How similar studies have gone: Previous research has shown promise in targeting similar epigenetic regulators in cancer treatment, indicating potential for success in this approach.
Where this research is happening
-
Sanford Burnham Prebys Medical Discovery Institute
La Jolla, United States Active
Researchers
- Principal investigator: Deshpande, Aniruddha J. — Sanford Burnham Prebys Medical Discovery Institute
- Study coordinator: Deshpande, Aniruddha J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.